POS0477 Defining Clinical Subgroups of Patients with Relapsing Polychondritis: A Latent Class and Decision Tree Analysis in Two Independent Prospective Cohorts

Background: Multiple factors contribute to diagnostic delay in patients with relapsing polychondritis (RP), including lack of awareness among healthcare providers, rarity, and disease heterogeneity. Using latent class analysis (LCA), phenotypic subgroups have been identified in a prospective cohort of patients with RP [1]. Identifying these subgroups can help clinicians to recognize patterns of organ involvement, facilitating prompt diagnosis and treatment. Objectives: This study aimed to validate previously identified clinical subgroups using LCA and develop a decision tree algorithm to accurately predict assignment of individual patients to these subgroups. Methods: Patients ≥ 18 years old who met diagnostic criteria for RP were included. All patients had a dynamic chest computerized tomography (CT) and audiometry. LCA was conducted in two independent prospective cohorts of patients with RP using the following variables: arthritis, tracheomalacia, bronchomalacia, subglottic stenosis, ear damage, nose damage, eye inflammation, and sensorineural hearing loss. Ear damage was defined by thickening of the cartilage or cauliflower ear. Nose damage was defined by saddle nose deformity or nasal septal perforation. Tracheomalacia and bronchomalacia were defined as ≥ 50% airway collapse on dynamic chest CT. Optimization of latent class models was performed using Bayesian information criterion (BIC) and Akaike information criterion (AIC). Decision tree analysis was performed to predict latent class group status. Results: 162 patients with RP were included in this study. Cohort #1 included 102 patients: 92 (90%) females; 93 (91%) Caucasians; median age 48 years (IQR= 38-59). Cohort #2 included 60 patients: 52 (86%) females; 52 (86 %) Caucasians; median age 44 years (IQR=38-52). Three clinical subgroups were identified by LCA in each cohort: Type 1 was characterized by ear damage, nose damage and subglottic stenosis, Type 2 was characterized by tracheomalacia and bronchomalacia, and Type 3 was characterized by absence of tracheomalacia. Tracheomalacia and ear damage were the two critical variables found on the decision tree that predicted latent class assignment in both cohorts. In cohort #1, the accuracy was 98% (R-square = 0.91) and in cohort #2 the accuracy was 100% (R-square=0.95). Conclusion: This study corroborates the existence of previously identified clinical subtypes of RP. Tracheomalacia and ear damage effectively categorize patients into these subgroups. These findings support the potential use of this subgrouping in clinical practice and clinical research design. REFERENCES: [1] Ferrada M, Rimland CA, et al. Defining Clinical Subgroups in Relapsing Polychondritis: A Prospective Observational Cohort Study. Arthritis Rheumatol . Aug 2020;72(8):1396-1402. doi:10.1002/art.41270 Acknowledgements: NIL . Disclosure of Interests: Shubhasree Banerjee: None declared, Carol McAlear: None declared, Peter Grayson: None declared, Peter A Merkel Kyverna, Q32, Sparrow, AbbVie, Alpine, Amgen, ArGenx, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, CSL Behring, GlaxoSmithKline, iCell, Interius, Kinevant, Kyverna, Metagenomia, Neutrolis, Novartis, NS Pharma, Q32, Quell, Regeneron, Sanofi, Sparrow, Takeda, Vistera. Research Support: AbbVie, Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eicos, Electra, GlaxoSmithKline, Neutrolis, Takeda, Marcela A. Ferrada: None declared. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.